Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects

Effects of insulin sensitization therapy

John M. Miles, David Wooldridge, Wayne J. Grellner, Sheryl Windsor, William L. Isley, Samuel Klein, William Harris

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Whether free fatty acid (FFA) rate of appearance (Ra) is increased in type 2 diabetes is controversial. To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate Ra in control subjects (n = 6) and individuals with poorly controlled, sulfonylurea-treated type 2 diabetes (HbA1c = 8.7 ± 0.2%, n = 20), the latter before and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n = 4), metformin (∼2,000 mg/day, n = 8), or placebo (n = 8). Subjects consumed a standard breakfast at 0800 h. Results in control subjects and type 2 diabetic subjects were compared at baseline. Integrated nocturnal FFA Ra (AUC1:00-8:00 A.M.) was ∼50% higher in type 2 diabetic subjects than in control subjects (29.4 ± 3.0 vs. 19.4 ± 3.9 mmol·m-2·7 h-1, respectively, P <0.05), whereas postprandial palmitate Ra (AUC0-240 min) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 ± 1.7 vs. 5.3 ± 1.0 mmol·m-2·4 h-1, respectively, P <0.01). After troglitazone treatment, nocturnal palmitate Ra did not change, but postprandial palmitate Ra decreased by ∼30% (P <0.05). Palmitate kinetics did not change with metformin or placebo treatment. In summary, nocturnal and postprandial FFA Ra is increased in type 2 diabetes. Postprandial lipolysis appears to be preferentially improved by thiazolidinediones compared with nocturnal lipolysis.

Original languageEnglish (US)
Pages (from-to)675-681
Number of pages7
JournalDiabetes
Volume52
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Palmitates
Nonesterified Fatty Acids
troglitazone
Insulin
Lipolysis
Type 2 Diabetes Mellitus
Metformin
Placebos
Therapeutics
Thiazolidinediones
Breakfast

Keywords

  • AUC, area under the curve
  • FFA, free fatty acid
  • LPL, lipoprotein lipase
  • MCR, metabolic clearance rate
  • R, rate of appearance
  • SNS, sympathetic nervous system

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Miles, J. M., Wooldridge, D., Grellner, W. J., Windsor, S., Isley, W. L., Klein, S., & Harris, W. (2003). Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: Effects of insulin sensitization therapy. Diabetes, 52(3), 675-681. https://doi.org/10.2337/diabetes.52.3.675

Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects : Effects of insulin sensitization therapy. / Miles, John M.; Wooldridge, David; Grellner, Wayne J.; Windsor, Sheryl; Isley, William L.; Klein, Samuel; Harris, William.

In: Diabetes, Vol. 52, No. 3, 01.03.2003, p. 675-681.

Research output: Contribution to journalArticle

Miles, JM, Wooldridge, D, Grellner, WJ, Windsor, S, Isley, WL, Klein, S & Harris, W 2003, 'Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: Effects of insulin sensitization therapy', Diabetes, vol. 52, no. 3, pp. 675-681. https://doi.org/10.2337/diabetes.52.3.675
Miles, John M. ; Wooldridge, David ; Grellner, Wayne J. ; Windsor, Sheryl ; Isley, William L. ; Klein, Samuel ; Harris, William. / Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects : Effects of insulin sensitization therapy. In: Diabetes. 2003 ; Vol. 52, No. 3. pp. 675-681.
@article{c8b9a61249614b72891a62c408bef384,
title = "Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: Effects of insulin sensitization therapy",
abstract = "Whether free fatty acid (FFA) rate of appearance (Ra) is increased in type 2 diabetes is controversial. To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate Ra in control subjects (n = 6) and individuals with poorly controlled, sulfonylurea-treated type 2 diabetes (HbA1c = 8.7 ± 0.2{\%}, n = 20), the latter before and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n = 4), metformin (∼2,000 mg/day, n = 8), or placebo (n = 8). Subjects consumed a standard breakfast at 0800 h. Results in control subjects and type 2 diabetic subjects were compared at baseline. Integrated nocturnal FFA Ra (AUC1:00-8:00 A.M.) was ∼50{\%} higher in type 2 diabetic subjects than in control subjects (29.4 ± 3.0 vs. 19.4 ± 3.9 mmol·m-2·7 h-1, respectively, P <0.05), whereas postprandial palmitate Ra (AUC0-240 min) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 ± 1.7 vs. 5.3 ± 1.0 mmol·m-2·4 h-1, respectively, P <0.01). After troglitazone treatment, nocturnal palmitate Ra did not change, but postprandial palmitate Ra decreased by ∼30{\%} (P <0.05). Palmitate kinetics did not change with metformin or placebo treatment. In summary, nocturnal and postprandial FFA Ra is increased in type 2 diabetes. Postprandial lipolysis appears to be preferentially improved by thiazolidinediones compared with nocturnal lipolysis.",
keywords = "AUC, area under the curve, FFA, free fatty acid, LPL, lipoprotein lipase, MCR, metabolic clearance rate, R, rate of appearance, SNS, sympathetic nervous system",
author = "Miles, {John M.} and David Wooldridge and Grellner, {Wayne J.} and Sheryl Windsor and Isley, {William L.} and Samuel Klein and William Harris",
year = "2003",
month = "3",
day = "1",
doi = "10.2337/diabetes.52.3.675",
language = "English (US)",
volume = "52",
pages = "675--681",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects

T2 - Effects of insulin sensitization therapy

AU - Miles, John M.

AU - Wooldridge, David

AU - Grellner, Wayne J.

AU - Windsor, Sheryl

AU - Isley, William L.

AU - Klein, Samuel

AU - Harris, William

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Whether free fatty acid (FFA) rate of appearance (Ra) is increased in type 2 diabetes is controversial. To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate Ra in control subjects (n = 6) and individuals with poorly controlled, sulfonylurea-treated type 2 diabetes (HbA1c = 8.7 ± 0.2%, n = 20), the latter before and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n = 4), metformin (∼2,000 mg/day, n = 8), or placebo (n = 8). Subjects consumed a standard breakfast at 0800 h. Results in control subjects and type 2 diabetic subjects were compared at baseline. Integrated nocturnal FFA Ra (AUC1:00-8:00 A.M.) was ∼50% higher in type 2 diabetic subjects than in control subjects (29.4 ± 3.0 vs. 19.4 ± 3.9 mmol·m-2·7 h-1, respectively, P <0.05), whereas postprandial palmitate Ra (AUC0-240 min) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 ± 1.7 vs. 5.3 ± 1.0 mmol·m-2·4 h-1, respectively, P <0.01). After troglitazone treatment, nocturnal palmitate Ra did not change, but postprandial palmitate Ra decreased by ∼30% (P <0.05). Palmitate kinetics did not change with metformin or placebo treatment. In summary, nocturnal and postprandial FFA Ra is increased in type 2 diabetes. Postprandial lipolysis appears to be preferentially improved by thiazolidinediones compared with nocturnal lipolysis.

AB - Whether free fatty acid (FFA) rate of appearance (Ra) is increased in type 2 diabetes is controversial. To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate Ra in control subjects (n = 6) and individuals with poorly controlled, sulfonylurea-treated type 2 diabetes (HbA1c = 8.7 ± 0.2%, n = 20), the latter before and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n = 4), metformin (∼2,000 mg/day, n = 8), or placebo (n = 8). Subjects consumed a standard breakfast at 0800 h. Results in control subjects and type 2 diabetic subjects were compared at baseline. Integrated nocturnal FFA Ra (AUC1:00-8:00 A.M.) was ∼50% higher in type 2 diabetic subjects than in control subjects (29.4 ± 3.0 vs. 19.4 ± 3.9 mmol·m-2·7 h-1, respectively, P <0.05), whereas postprandial palmitate Ra (AUC0-240 min) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 ± 1.7 vs. 5.3 ± 1.0 mmol·m-2·4 h-1, respectively, P <0.01). After troglitazone treatment, nocturnal palmitate Ra did not change, but postprandial palmitate Ra decreased by ∼30% (P <0.05). Palmitate kinetics did not change with metformin or placebo treatment. In summary, nocturnal and postprandial FFA Ra is increased in type 2 diabetes. Postprandial lipolysis appears to be preferentially improved by thiazolidinediones compared with nocturnal lipolysis.

KW - AUC, area under the curve

KW - FFA, free fatty acid

KW - LPL, lipoprotein lipase

KW - MCR, metabolic clearance rate

KW - R, rate of appearance

KW - SNS, sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=0037339730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037339730&partnerID=8YFLogxK

U2 - 10.2337/diabetes.52.3.675

DO - 10.2337/diabetes.52.3.675

M3 - Article

VL - 52

SP - 675

EP - 681

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -